TherapeuticsMD Company Insiders

TXMD Stock  USD 2.25  0.03  1.32%   
TherapeuticsMD's insiders are aggressively buying. The analysis of insiders' sentiment of trading TherapeuticsMD stock suggests that all insiders are extremely bullish at this time. TherapeuticsMD employs about 1 people. The company is managed by 14 executives with a total tenure of roughly 35 years, averaging almost 2.0 years of service per executive, having 0.07 employees per reported executive.
Robert Finizio  CEO
Co-Founder, CEO and Director
Michael Donegan  President
Vice President - Finance

Insider Sentiment 100

 Aggressively Buying

 
Selling
 
Buying

Latest Trades

2025-12-23Tommy G ThompsonAcquired 8400 @ 1.67View
2025-04-14Tommy G ThompsonAcquired 325 @ 1View
2025-04-09Marlan D WalkerAcquired 1136 @ 0.87View
Monitoring TherapeuticsMD's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TherapeuticsMD. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.

TherapeuticsMD's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with TherapeuticsMD's future performance. Based on our forecasts, it is anticipated that TherapeuticsMD will maintain a workforce of about 5 employees by March 2026.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

TherapeuticsMD Management Team Effectiveness

The company has return on total asset (ROA) of (0.0273) % which means that it has lost $0.0273 on every $100 spent on assets. This is way below average. TherapeuticsMD's management efficiency ratios could be used to measure how well TherapeuticsMD manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2026, Return On Tangible Assets is expected to decline to -0.08. In addition to that, Return On Capital Employed is expected to decline to -0.17. At present, TherapeuticsMD's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 4.8 M, whereas Other Current Assets are forecasted to decline to about 1.4 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 13.9 M, whereas Net Loss is projected to grow to (147.4 M). The market capitalization of TherapeuticsMD is $26.04 Million. About 69.21 % of TherapeuticsMD outstanding shares are held by general public with 1.54 (%) owned by insiders and only 29.25 % by institutional holders. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
1999-03-31
Previous Quarter
11.6 M
Current Value
11.6 M
Avarage Shares Outstanding
6.3 M
Quarterly Volatility
15.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Some institutional investors establish a significant position in stocks such as TherapeuticsMD in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of TherapeuticsMD, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

TherapeuticsMD Workforce Comparison

TherapeuticsMD is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 393,450. TherapeuticsMD adds roughly 1.0 in number of employees claiming only tiny portion of equities under Health Care industry.

TherapeuticsMD Profit Margins

The company has Profit Margin (PM) of 0.11 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.38) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.38.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.930.88
Notably Up
Slightly volatile

TherapeuticsMD Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TherapeuticsMD insiders, such as employees or executives, is commonly permitted as long as it does not rely on TherapeuticsMD's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, TherapeuticsMD insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
1.1667
7
6
 33,781 
 31,470 
2023-12-01
0.6667
2
3
 947,192 
 89,050 
2023-06-01
0.8889
8
9
 372,777 
 62,114 
2023-03-01
1.5
9
6
 130,305 
 6,546 
2022-12-01
0.7647
13
17
 53,169 
 76,506 
2022-09-01
2.0
22
11
 788,323 
 37,594 
2022-03-01
10.0
10
1
 6,020,000 
 230,000 
2021-12-01
2.5
5
2
 2,035,000 
 144,790 
2021-09-01
2.1667
39
18
 13,704,685 
 1,818,848 
2021-06-01
0.5833
7
12
 543,334 
 765,221 
2021-03-01
0.2857
2
7
 358,000 
 1,044,428 
2020-06-01
23.0
23
1
 2,764,908 
 434,814 
2020-03-01
3.5
14
4
 3,541,000 
 900,000 
2018-12-01
0.2979
28
94
 2,795,385 
 9,465,880 
2018-09-01
0.5862
17
29
 1,605,614 
 3,402,014 
2018-03-01
6.0
6
1
 1,320,000 
 25,000 
2017-12-01
1.0
1
1
 5,000 
 0.00 
2017-09-01
1.0
1
1
 5,000 
 150,000 
2016-06-01
2.0
2
1
 122,744 
 100,000 
2015-12-01
7.0
14
2
 2,775,000 
 0.00 
2015-09-01
3.0
3
1
 23,843 
 50,000 
2015-06-01
1.6
8
5
 147,000 
 240,000 
2014-12-01
0.375
3
8
 190,000 
 295,000 
2014-06-01
2.2
11
5
 412,052 
 310,000 
2014-03-01
0.1803
11
61
 457,500 
 11,534,741 
2013-12-01
1.0
1
1
 250,000 
 0.00 
2013-09-01
5.0
5
1
 135,728 
 1,600,000 
2013-06-01
4.0
8
2
 575,000 
 2,631,579 
2012-03-01
0.4
2
5
 600,000 
 92,057 
2011-12-01
0.6667
4
6
 1,800,000 
 296,628 
2005-09-01
0.6
3
5
 112,117 
 39,063 
2005-03-01
1.5
3
2
 2,500 
 2,000 
2004-12-01
2.0
2
1
 2,000 
 0.00 

TherapeuticsMD Notable Stakeholders

A TherapeuticsMD stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as TherapeuticsMD often face trade-offs trying to please all of them. TherapeuticsMD's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting TherapeuticsMD's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert FinizioCo-Founder, CEO and DirectorProfile
Governor ThompsonExecutive ChairmanProfile
Michael DoneganVice President - FinanceProfile
Mitchell KrassanExecutive VP and Chief Strategy Performance OfficerProfile
Hugh MBAPres DirectorProfile
MD FACOGCoFounder,CoCEO OfficerProfile
Douglas SteelmanVice AccessProfile
Benjamin FoulkVice ResourcesProfile
Dedra LydenVice InitiativesProfile
Joseph ZieglerPrincipal OfficerProfile
Daniella SilvaChief OfficerProfile
Mark GlickmanCoCEO OfficerProfile
Marlan JDChief OfficerProfile
Bharat WarrierChief OfficerProfile
String symbol = request.getParameter("s");

About TherapeuticsMD Management Performance

The success or failure of an entity such as TherapeuticsMD often depends on how effective the management is. TherapeuticsMD management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of TherapeuticsMD management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the TherapeuticsMD management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.07)(0.08)
Return On Capital Employed(0.16)(0.17)
Return On Assets(0.06)(0.07)
Return On Equity(0.09)(0.09)
Please note, the presentation of TherapeuticsMD's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, TherapeuticsMD's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of TherapeuticsMD's management manipulating its earnings.

TherapeuticsMD Workforce Analysis

Traditionally, organizations such as TherapeuticsMD use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare TherapeuticsMD within its industry.

TherapeuticsMD Manpower Efficiency

Return on TherapeuticsMD Manpower

Revenue Per Employee1.8M
Revenue Per Executive125.8K
Net Loss Per Employee2.3M
Net Loss Per Executive165.1K
Working Capital Per Employee7.1M
Working Capital Per Executive506.6K

Complementary Tools for TherapeuticsMD Stock analysis

When running TherapeuticsMD's price analysis, check to measure TherapeuticsMD's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TherapeuticsMD is operating at the current time. Most of TherapeuticsMD's value examination focuses on studying past and present price action to predict the probability of TherapeuticsMD's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TherapeuticsMD's price. Additionally, you may evaluate how the addition of TherapeuticsMD to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments